Because the present study is a retrospective population-based study, data regarding socioeconomic status, family history of breast cancer, lifestyle factors, HER2 status, and administration of and compliance with neoadjuvant or adjuvant systemic therapies were limited. Here, ERBB2 is linked to breast carcinoma.